Monoclonal gammopathy of neurological significance: a case report and a novel approach
Main Article Content
Keywords
MGCS, MGNS, anti-MAG, Plasma-Exchange, Rituximab
Abstract
There is increasing evidence regarding gammopathy of clinical significance (MGCS), conditions in which there is paraprotein-mediated tissue and organ damage via mechanisms independent of tumor growth. There is no standard treatment for these novel entities. We describe a case of a 61 years old male presenting with a monoclonal gammopathy of neurological significance (MGNS) treated with four weekly doses of Rituximab (RTX), without benefit, and then with a novel protocol.
Downloads
Abstract 258
PDF Downloads 182
HTML Downloads 36
Article Sidebar
Article Details
How to Cite
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Transfer of Copyright and Permission to Reproduce Parts of Published Papers. Authors will grant copyright of their articles to the Institute of Hematology, Catholic University, Rome . No formal permission will be required to reproduce parts (tables or illustrations) of published papers, provided the source is quoted appropriately and reproduction has no commercial intent. Reproductions with commercial intent will require written permission and payment of royalties.